This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.
Will Pfizer (PFE) Deliver a Beat This Earnings Season?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.
Bear of the Day: Viatris (VTRS)
by Tracey Ryniec
This newly created healthcare leader disappoints on full-year guidance.
Theravance (TBPH) Q4 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.
Viatris (VTRS) Declines on Lackluster Outlook, Announces Dividend
by Zacks Equity Research
Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.
Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat
by Zacks Equity Research
Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.
Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Is Mylan (VTRS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative
by Zacks Equity Research
Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.
3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
by Zacks Equity Research
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.